Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (7749)	11/17/1998 5:50:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

I thought the new patent was great, but I wonder why the market disregards it. Lets see what they take into the clinic and also what kind of deal if any they can make with I-Prex and Mycoprex. LLY just generated $1.6 billion getting out of a costly mistake. Just another large player with funds that might be redeployed in the biotech sector. Don't see how the Hoechst merger will help biotechs. It may hurt as they relook at their combined relationships and sort out those which can be terminated. Trying to meld the two companies should also slow down looking at new partnerships or agreements.